Rallybio Q2 revenue falls, net loss narrows

Reuters08-07

Rallybio <a href="https://laohu8.com/S/QTWO">Q2</a> revenue falls, net loss narrows

Overview

Rallybio Q2 revenue dips to $0.2 mln from $0.3 mln in 2024
Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024
Co sells REV102 interest for up to $25 mln, extending cash runway

Outlook

Rallybio expects RLYB116 study data in 3Q and 4Q 2025
Company's cash runway extended into mid-2027 after REV102 sale
Rallybio anticipates complete complement inhibition in RLYB116 study
Company focuses RLYB116 on PTR and APS conditions

Result Drivers

REVENUE DECLINE - Decrease in revenue attributed to changes in collaboration agreements with Johnson & Johnson
R&D EXPENSES DROP - Lower R&D expenses due to decreased development costs for RLYB212 and other programs
CASH INFUSION - Sale of REV102 interest to Recursion Pharmaceuticals extends cash runway into mid-2027

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Net Income		-$9.70 mln
Q2 Basic EPS		-$0.22
Q2 Income From Operations		-$10.06 mln
Q2 Operating Expenses		$10.27 mln

Press Release: ID:nBw38yYrla

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2557856872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557856872","market":"us","top_or_hot":-1,"title":"Rallybio Q2 revenue falls, net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rallybio <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls, net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Rallybio Q2 revenue dips to $0.2 mln from $0.3 mln in 2024</p></li><li><p>Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024</p></li><li><p>Co sells REV102 interest for up to $25 mln, extending cash runway</p></li></ul><p><span>Outlook</span></p><ul><li><p>Rallybio expects RLYB116 study data in 3Q and 4Q 2025</p></li><li><p>Company's cash runway extended into mid-2027 after REV102 sale</p></li><li><p>Rallybio anticipates complete complement inhibition in RLYB116 study</p></li><li><p>Company focuses RLYB116 on PTR and APS conditions</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>REVENUE DECLINE - Decrease in revenue attributed to changes in collaboration agreements with Johnson &amp; Johnson</p></li><li><p>R&amp;D EXPENSES DROP - Lower R&amp;D expenses due to decreased development costs for RLYB212 and other programs</p></li><li><p>CASH INFUSION - Sale of REV102 interest to <a href=\"https://laohu8.com/S/RXRX\">Recursion</a> Pharmaceuticals extends cash runway into mid-2027</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$9.70 mln</p></td><td></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$0.22</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td></td><td><p>-$10.06 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$10.27 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw38yYrla</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rallybio Q2 revenue falls, net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRallybio Q2 revenue falls, net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-07 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rallybio <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls, net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Rallybio Q2 revenue dips to $0.2 mln from $0.3 mln in 2024</p></li><li><p>Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024</p></li><li><p>Co sells REV102 interest for up to $25 mln, extending cash runway</p></li></ul><p><span>Outlook</span></p><ul><li><p>Rallybio expects RLYB116 study data in 3Q and 4Q 2025</p></li><li><p>Company's cash runway extended into mid-2027 after REV102 sale</p></li><li><p>Rallybio anticipates complete complement inhibition in RLYB116 study</p></li><li><p>Company focuses RLYB116 on PTR and APS conditions</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>REVENUE DECLINE - Decrease in revenue attributed to changes in collaboration agreements with Johnson &amp; Johnson</p></li><li><p>R&amp;D EXPENSES DROP - Lower R&amp;D expenses due to decreased development costs for RLYB212 and other programs</p></li><li><p>CASH INFUSION - Sale of REV102 interest to <a href=\"https://laohu8.com/S/RXRX\">Recursion</a> Pharmaceuticals extends cash runway into mid-2027</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$9.70 mln</p></td><td></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$0.22</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td></td><td><p>-$10.06 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$10.27 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw38yYrla</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLYB","symbol_name":"Rallybio Corp.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX95E5C2:2","article_id":"2557856872","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557856872","pubTimestamp":1754568592,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rallybio Q2 revenue falls, net loss narrowsOverviewRallybio Q2 revenue dips to $0.2 mln from $0.3 mln in 2024Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024Co sells REV102 interest for up to $2","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RLYB":"Rallybio Corp.","JNJ":"强生"},"translate_title":"Rallybio第二季度收入下降，净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9,"RLYB":0.9},"content_text":"Rallybio Q2 revenue falls, net loss narrowsOverviewRallybio Q2 revenue dips to $0.2 mln from $0.3 mln in 2024Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024Co sells REV102 interest for up to $25 mln, extending cash runwayOutlookRallybio expects RLYB116 study data in 3Q and 4Q 2025Company's cash runway extended into mid-2027 after REV102 saleRallybio anticipates complete complement inhibition in RLYB116 studyCompany focuses RLYB116 on PTR and APS conditionsResult DriversREVENUE DECLINE - Decrease in revenue attributed to changes in collaboration agreements with Johnson & JohnsonR&D EXPENSES DROP - Lower R&D expenses due to decreased development costs for RLYB212 and other programsCASH INFUSION - Sale of REV102 interest to Recursion Pharmaceuticals extends cash runway into mid-2027Key DetailsMetricBeat/MissActualConsensus EstimateQ2 Net Income-$9.70 mlnQ2 Basic EPS-$0.22Q2 Income From Operations-$10.06 mlnQ2 Operating Expenses$10.27 mlnPress Release: ID:nBw38yYrla(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557856872","isCrawlerRequest":true}